Status:

COMPLETED

Study Assessing Safety and Immunogenicity of IC43 Vaccination Against Pseudomonas Aeruginosa in Healthy Volunteers

Lead Sponsor:

Valneva Austria GmbH

Conditions:

Healthy

Eligibility:

All Genders

18-65 years

Phase:

PHASE1

Brief Summary

The objective is to confirm the optimal dose of IC43 in regard to immunogenicity, safety and tolerability.

Detailed Description

The study will be designed as a multi-center, observer-blinded, randomized, placebocontrolled phase 1 study in healthy adult subjects of 18 to 65 years of age. A total of 160 healthy male and female s...

Eligibility Criteria

Inclusion

  • written informed consent obtained prior to study entry
  • healthy adults aged between 18 and 65 years
  • no clinically relevant pathological findings in any of the investigations at the Screening visit. Minor deviations of laboratory values from the normal range may be accepted, if judged by the investigator to have no clinical relevance
  • In female subjects either childbearing potential terminated by surgery or a negative serum pregnancy test during screening and the willingness not to become pregnant during the entire study period by practicing reliable methods of contraception

Exclusion

  • History of autoimmune diseases and malignancies
  • Active or passive vaccination 4 weeks before and during the entire study protocol
  • Use of any other investigational or non-registered drug or vaccine in addition to the study vaccine during the study period or within 30 days preceding the first dose of study vaccine
  • History of severe hypersensitivity reactions and anaphylaxis
  • Known hypersensitivity or allergic reactions to one of the components of the vaccine
  • Clinically significant diseases as judged by the investigator
  • Immunodeficiency due to immunosuppressive therapy
  • A family history of congenital or hereditary immunodeficiency

Key Trial Info

Start Date :

September 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

September 1 2009

Estimated Enrollment :

157 Patients enrolled

Trial Details

Trial ID

NCT00778388

Start Date

September 1 2008

End Date

September 1 2009

Last Update

October 19 2012

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Univ.-Prof. Dr. Bernd Jilma

Vienna, Vienna, Austria, 1090

2

Dr. Daniel Sehrt

Göttingen, Göttingen, Germany

3

Dr. Jutta Harten

Münster, Münster, Germany